SUMMARY The discovery of DNA markers closely linked to the gene for Huntington's disease (HD) has allowed development of predictive and prenatal testing programmes for HD. This report describes four different approaches to prenatal testing for HD which have arisen during a pilot predictive and prenatal testing program in British Columbia, Canada. In the first approach (exclusion testing), the at risk parent cannot or prefers not to learn of his/her HD status. Two other approaches involve definitive testing of a fetus when a parent is determined to be at increased risk to have inherited the HD gene or is affected with Huntington's disease. The fourth approach is a stepwise combination of the above two methods which we refer to as 'exclusiondefinitive' testing. These different approaches introduce a variety of challenging counselling and ethical issues. The role of each approach to prenatal testing in the management of Huntington's disease awaits 'the results of this and other predictive and prenatal testing programmes.
Huntington's disease is an inherited autosomal dominant neuropsychiatric disorder that usually manifests in mid-life with abnormal involuntary movement, personality change, and dementia. Although the cause of the disease is unknown, coordinated efforts have mapped the mutant gene to the distal end of the short arm of chromosomeA4.14 The recent discovery of a number of linked polymorphic DNA markers for HD has made it possible to determine whether subjects at (fig 2) . This implies that the fetus is at very low risk (<4%) of having inherited the HD gene. On the basis of this information the parents decided to continue the pregnancy.
Discussion
The use of polymorphic DNA markers linked to the locus for Huntington's disease has made predictive and prenatal testing possible. Using three DNA markers (D4S10, D4S62, and D4S95) and a total of seven enzymes (HincII-D4S62, EcoRI, Bgll, HindIII-D4S1O, Accl, TaqI, MboI-D4S95), none of 50 controls was found to be homozygous for all the markers. The informativeness of such a test is now only limited by the availability of DNA from affected and unaffected family members and the recombination fraction between the linked markers and the HD locus. 5 The case situation, which we refer to as exclusiondefinitive testing, enables the 50% at risk parent to maximise the a priori 75% probability that the fetus has not inherited the HD gene. The 50% probability that the fetus is at very low risk by virtue of not having the affected maternal grandmother's chromosome is either confirmed or ruled out by the exclusion testing step. In the event that the fetus is determined to have inherited the affected grandmother's chromosome, the phase of the markers segregating with the gene for HD is determined. This care for the baby with the realisation that increasing responsibility for raising the child will fall on the unaffected parent as the disease progresses.
It is apparent that options for prenatal testing are varied and clearly more complex than initially suspected. An appropriate choice is dependent upon how much information candidates wish to learn about themselves or the fetus or both and what is technically possible. The decision making process incorporates the parents' values, such as the importance of having children and attitudes towards termination, as well as their feelings about their perceived ability to cope with the stress of learning of an increased risk and their hopes for treatment for HD in the future. A detailed clinical assessment of the couple's ability to cope with this information is necessary. In the end, however, the candidate and his/her partner choose an option based on their current needs, tolerance for risk factors, and perceived impact of the various possible outcomes.
The precise role of each of these approaches to prenatal testing for HD awaits the long term follow up of this and other predictive testing programmes following detailed and in depth analysis. In the exclusion-definitive stepwise approach, the proband and her partner are prepared to continue a pregnancy if they can be reassured that the fetus is at low risk, at the expense of possibly having to learn of the at risk partner's status. For the mother recently diagnosed as having HD, prenatal testing enabled her to have a child determined to be at very low risk for HD. At least one major concern, that is, transmitting the mutant gene to her offspring, has been lifted for this affected person.
